Axovant Reports Financial Results for the First Fiscal Quarter of 2015 and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Axovant Sciences Ltd. (AXON) Reports Q1 Loss of $0.35, Names CFO
August 11, 2015 4:24 PM EDTAxovant Sciences Ltd. (NYSE: AXON) reported Q1 EPS of ($0.35).
"We remain on track to commence the confirmatory phase 3 study for RVT-101 in Alzheimer's disease in the fourth quarter of 2015," stated Vivek Ramaswamy, Chief Executive Officer of Axovant Sciences, Inc. "We look forward to providing additional updates later this year regarding our progress towards building a dementia solutions company."
Leadership Update
Axovant is pleased to announce the appointment of Gregory Weinhoff, MD, MBA as the Chief Financial Officer... More
